Immunogenicity of biologicals: the role of post-translational modifications

2017-04-05 Although produced under strict quality control(s) nascent endogenous proteins and glycoproteins (P/GP) are structurally heterogeneous and subject to further structural changes throughout their in vivo… Read More »

Pharmacists prefer generic OTC medicines

2017-04-03 In the US, the use of generics has been lacking due to hesitation from consumers over whether generics are as safe and effective as brand-name… Read More »

Effectiveness of ESAs in treating anaemia in kidney disease and cancer patients

2017-03-31 Erythropoiesis-stimulating agents (ESAs) are biological analogues of human erythropoietin used for the treatment of anaemia associated with chronic kidney disease (CKD) and chemotherapy treatment in… Read More »

Switching between generics of anti-epileptic drugs

2017-03-29 Two different generic versions of anti-epilepsy medicine lamotrigine have been shown to be bioequivalent in patients with epilepsy and to not cause any differences in… Read More »

Monoclonal antibodies and the challenge of substitution

2017-03-27 Healthcare payers are eagerly awaiting the arrival of biosimilar competition in the innovative monoclonal antibody sector in order to drive down drug prices and increase… Read More »

South Korean pharma market to reach US$20 billion by 2020

2017-03-24 The pharmaceutical market in South Korea is on the increase and is expected to reach more than US$20 billion by 2020. According to a report… Read More »

Cost-effectiveness analysis and incentivizing innovation

2017-03-22 In the paper by Santiago Moreno and Joshua Ray, the controversial role that conventional cost-effectiveness analysis (CEA) plays in incentivizing innovation is revealed [1]. Detractors… Read More »

Is a new pathway for NBCDs on the way in the US?

2017-03-20 The US Food and Drug Administration (FDA) does not formerly recognize non-biological complex drugs (NBCDs), with originators required to follow the new drug application (NDA)… Read More »

Switching between different ESAs

2017-03-17 Switching between reference biologicals and biosimilars can be a contentious issue. A study from Italy, however, has found that this phenomenon is not limited to… Read More »

Japan proving to be a favourable market for biosimilars

2017-03-15 Uptake of biosimilars in Japan is on a par with generics use for some products, making Japan a lucrative market for biosimilars makers. In Japan,… Read More »

Page 2 of 49 « Previous1 2 3 4 5 Next »... 49
Go Back Print